Document is current
Any future updates will be listed below
-
Authors
Colwell, Michael J. http://orcid.org/0000-0001-7846-2879
Tagomori, Hosana http://orcid.org/0000-0002-9883-4577
Shang, Fei
Cheng, Hoi Iao
Wigg, Chloe E.
Browning, Michael http://orcid.org/0000-0001-9108-3144
Cowen, Philip J. http://orcid.org/0000-0001-5518-6138
Murphy, Susannah E.
Harmer, Catherine J. http://orcid.org/0000-0002-1609-8335
- License Information
-
More Information
Article History
Received: 30 September 2023
Accepted: 9 July 2024
First Online: 9 August 2024
Competing interests
: C.H. has received consultancy fees from P1vital Ltd., Janssen Pharmaceuticals, UCB Pharma, Sage Therapeutics, Pfizer, Zogenix, Compass Pathways, and Lundbeck, and is a director of the company TnC Psychiatry and Neuroscience. S.M. has received consultancy fees from Zogenix, Sumitomo Dainippon Pharma, P1vital Ltd., UCB Pharma and Janssen Pharmaceuticals. C.H. and S.M. hold grant income from Zogenix, UCB Pharma, Syndesi and Janssen Pharmaceuticals. C.H. and P.C. hold grant income from a collaborative research project with Pfizer. M.B. has received travel expenses from Lundbeck for attending conferences and has acted as a consultant for J&J, Novartis, Boehringher and CHDR. He previously owned shares in P1vital Ltd. The other authors report no conflicts of interest.
